Introduction
============

The endosomal sorting complexes required for transport (ESCRTs) are recruited to the cytosolic surface of endosomes, where they selectively package ubiquitinated transmembrane protein cargoes into the intralumenal vesicles (ILVs) of multivesicular bodies (MVBs). The ILVs and their cargoes are subsequently degraded upon fusion of MVBs with lysosomes. ESCRT-0, -I, and -II are stable heteromeric complexes, each containing subunits that bind directly to ubiquitin (Ub) linkages on the cytosolic domains of cargoes ([@bib34]; [@bib35]). Recent studies indicate that ESCRT-I and -II can also induce membrane invaginations of nascent ILVs in vitro ([@bib52]) and that ESCRT-II can stimulate assembly of ESCRT-III ([@bib16]; [@bib42]).

The polymerization of ESCRT-III subunits is required for completion of ILV budding. Genetic and biochemical studies of ESCRT-III proteins from *Saccharomyces cerevisiae* have contributed much to our understanding about assembly of the complex, principles that are likely to be generally conserved. ESCRT-III in yeast is comprised of four core subunits (Snf7, Vps20, Vps24, and Vps2; [@bib6]), the most abundant of which is Snf7 ([@bib47]). Polymerization of Snf7 on membranes is stimulated upon binding Vps20, which relieves an autoinhibitory intramolecular interaction between the N- and C-terminal regions of Snf7 ([@bib47]; [@bib42]). Membrane-associated Snf7 polymers are thought to be capped by Vps24, which recruits Vps2 ([@bib6]; [@bib47]). In turn, Vps2 promotes activation of the AAA-ATPase Vps4, which catalyzes disassembly of ESCRT-III and recycling of its subunits from membranes to the cytosol ([@bib5]; [@bib6]). Did2, Ist1, and Vps60 are three accessory ESCRT-III subunits that appear to serve primarily as regulators of Vps4 activity ([@bib29]; [@bib3]; [@bib11]; [@bib40]).

In vitro reconstitution of ESCRT-III assembly on synthetic membranes revealed that excess amounts of the yeast core ESCRT-III subunits deform liposomes ([@bib42]) and drive both the formation and detachment of lumenal membrane invaginations ([@bib53]). In limiting amounts, however, ESCRT-III subunits lack the ability to deform the membrane and, instead, their activity is restricted to facilitating the severing of membrane invaginations generated by ESCRT-I and -II ([@bib52]). These observations suggest that ESCRT-III is responsible for execution of the membrane scission step during ILV formation. Consistent with these in vitro findings, mammalian ESCRT-III is required during cytokinesis for midbody abscission and for the detachment of fully assembled retroviruses from the plasma membrane ([@bib27]). Both abscission and retroviral budding require membranes to be severed in a manner that is topologically equivalent to ILV formation at MVBs, and all three processes are disabled by inhibiting Vps4 function ([@bib14]; [@bib9]). Overexpression of catalytically inactive Vps4 in mammalian cells dramatically increases the frequency of ILV budding profiles and reduces the number of freely detached ILVs at MVBs ([@bib41]). However, based on studies of reconstituted ILV budding in vitro ([@bib53]; [@bib52]), Vps4 is thought to function indirectly in membrane scission by recycling ESCRT-III subunits for repeated rounds of assembly.

In addition to its membrane scission activity, ESCRT-III is required for coordinating the deubiquitination of transmembrane protein cargoes before their enclosure within ILVs. In humans, two distinct Ub hydrolases bind directly to ESCRT-III via microtubule-interacting and trafficking (MIT) domains ([@bib1]; [@bib49]; [@bib39]), and in yeast, recruitment of the Ub hydrolase Doa4 to ESCRT-III is promoted by Bro1, which binds both to Snf7 and to the Doa4 catalytic domain ([@bib24]; [@bib20]; [@bib36]). Bro1 and its closest human orthologue, Alix, each have a conserved N-terminal Bro1 domain that binds directly to Snf7 and CHMP4 proteins, respectively ([@bib20]; [@bib13]). Although this interaction is essential for Alix to promote retrovirus budding ([@bib13]), the means by which it contributes to ESCRT-III function in membrane scission remain unclear. In yeast, Bro1 likely has a role in ILV budding independent of its activity in regulating deubiquitination because ILV formation is strongly impaired by deletion of *BRO1* but not *DOA4* ([@bib36]). In this study, we report that binding of Bro1 to Snf7 enhances the stability of ESCRT-III in vivo and inhibits Vps4-mediated disassembly of the complex in vitro. This effect correlates with a reduced efficiency in detachment of ILVs from the limiting endosomal membrane. Conversely, mutation of the Bro1-binding site in Snf7 strongly inhibits vesicle formation and cargo sorting. These results implicate Bro1 as a regulator of ESCRT-III disassembly and membrane scission activity.

Results
=======

The Bro1 domain binds a MIM1-like motif in the Snf7 subunit of ESCRT-III
------------------------------------------------------------------------

Yeast two-hybrid analysis (unpublished data) was used to map the amino acids in Snf7 required for its interaction with the Bro1 domain of yeast Bro1 ([Fig. 1 A](#fig1){ref-type="fig"}). This site is centered around residues Leu-231 and Leu-234 at the C terminus of Snf7, which resembles the site in CHMP4 proteins that binds the Bro1 domain of Alix ([@bib26]) and is similar to the MIM1 motif that was identified in Vps2/CHMP2 and Did2/CHMP1 proteins ([@bib31]; [@bib45]). The MIT domain of Vps4 has relatively strong affinity for MIM1 of Vps2/CHMP2 and Did2/CHMP1 but binds poorly to the MIM1-like site in CHMP4 proteins ([@bib19]), which is consistent with the lack of in vitro binding between purified Snf7 and Vps4 ([@bib43]; unpublished data).

![**The Bro1 domain binds a MIM1-like motif in Snf7.** (A) Schematic diagrams of Bro1 and Snf7, including the amino acid sequence alignment of MIM1-like motifs from yeast Snf7 and human CHMP4a. (B) In vitro pull-downs of purified GST or GST-Bro1 domain incubated with bacterial lysates expressing Snf7-HA or Snf7^L231A/L234A^-HA. GST and GST-Bro1 domain inputs were loaded at 10% of their total used in each pull-down. IB, immunoblotting. (C) Fluorescence and DIC microscopy of *vps4Δ*, *vps4Δ snf7Δ*, and *vps4Δ snf7^L231/234A^* cells expressing GFP-Bro1 domain or GFP-Bro1. Arrowheads indicate where GFP does (closed) or does not (open) colocalize with FM4-64--labeled class E compartments. Bars, 2 µm.](JCB_201007018_RGB_Fig1){#fig1}

Leu-231 and Leu-234 in the MIM1-like site of Snf7 were essential for its in vitro binding to the Bro1 domain of yeast Bro1 ([Fig. 1 B](#fig1){ref-type="fig"}). In vivo, these residues were also required for Snf7 to mediate endosomal localization of the Bro1 domain fused to GFP ([Fig. 1 C](#fig1){ref-type="fig"}). However, full-length Bro1-GFP weakly localized to endosomes despite disruption of the Bro1 domain--binding site in Snf7 (*snf7^L231A/L234A^*; [Fig. 1 C](#fig1){ref-type="fig"}), which matches our previous observation that full-length Bro1 weakly localizes to endosomes despite mutation of the Snf7 interaction surface in the Bro1 domain, whereas the same mutation completely disables endosomal localization of the Bro1 domain alone ([@bib20]).

Bro1 binding to Snf7 enhances the stability of ESCRT-III polymers in vivo
-------------------------------------------------------------------------

The position of the Bro1 domain--binding site at the C terminus of Snf7 ([Fig. 1](#fig1){ref-type="fig"}) suggested that Bro1 might act like Vps20 to relieve Snf7 autoinhibition ([@bib47]; [@bib42]), thereby promoting Snf7 polymerization and incorporation into ESCRT-III. However, it was previously shown that Bro1 is not essential for Snf7 polymerization based on the analysis of cells in which ESCRT-III disassembly by the Vps4 ATPase had been disabled by deletion of the *VPS4* gene ([@bib47]). Therefore, we investigated whether Bro1 might influence Snf7 polymerization in the context of functional Vps4 by examining the distribution of Snf7 in detergent-solubilized yeast membranes separated by isopycnic density gradient centrifugation. In extracts from wild-type cells, the majority of Snf7 was seen in low density fractions, but a small amount (19%) was detected in higher density fractions ([Fig. 2, A and B](#fig2){ref-type="fig"}). This high density pool of Snf7 likely corresponds to the transient ESCRT-III complexes that were reported to exist at steady-state ([@bib47]) because the same gradient fractions contained ∼90% of Snf7 in extracts from *vps4Δ* cells ([Fig. 2, A and B](#fig2){ref-type="fig"}) in which ESCRT-III is irreversibly trapped as an assembled complex ([@bib5]; [@bib47]). The polymeric Snf7 we observed had the same properties that were reported previously ([@bib47]) because its stabilization upon deletion of *VPS4* was largely dependent on Vps20 but not Bro1 ([Fig. 2, A and B](#fig2){ref-type="fig"}). Moreover, recombinant Snf7 that was expressed in bacteria and isolated as a soluble polymer by size-exclusion chromatography before being subjected to isopycnic density gradient centrifugation also migrated to high density fractions ([Fig. S1 A](http://www.jcb.org/cgi/content/full/jcb.201007018/DC1)).

![**Overexpression of Bro1 or the Bro1 domain stabilizes ESCRT-III polymers at endosomes.** (A) Western blot analysis of detergent-solubilized yeast membranes resolved by isopycnic density gradient centrifugation. Inclusion of 1% Triton X-100 throughout the gradients yielded identical sedimentation profiles. (B) Quantitation of triplicate gradients from A.](JCB_201007018_GS_Fig2){#fig2}

Although a relatively minor percentage of membrane-associated Snf7 was polymeric in extracts from wild-type cells (19%), the percentage of polymeric Snf7 increased upon overexpression of either full-length Bro1 or the Bro1 domain (∼29% and ∼27%, respectively; [Fig. 2, A and B](#fig2){ref-type="fig"}). This effect required that Snf7 first undergo activation by Vps20 because overexpression of the Bro1 domain in *vps20Δ* cells failed to enhance detection of polymeric Snf7 ([Fig. 2, A and B](#fig2){ref-type="fig"}). Bro1 domain overexpression also did not cause an increase in the amount of mutant *snf7^L231A/L234A^* that could be detected as a polymer, and wild-type Snf7 was similarly unaffected by overexpression of a mutant Bro1 domain that lacks the Snf7-binding site (Fig. S1 B), indicating that the effect of Bro1 domain overexpression toward stabilizing ESCRT-III depends on its ability to bind Snf7. Bro1 domain overexpression caused a similar shift toward high density gradient fractions for another core ESCRT-III subunit, Vps24 ([Fig. S2](http://www.jcb.org/cgi/content/full/jcb.201007018/DC1)), although concomitant shifts in ESCRT-I or ESCRT-II were not observed (not depicted). However, the total amounts of membrane-associated Snf7 and Vps24 were not significantly altered by overexpression of the Bro1 domain ([Fig. S3](http://www.jcb.org/cgi/content/full/jcb.201007018/DC1)), indicating that the membrane recruitment step preceding ESCRT-III assembly was not enhanced. Moreover, we did not detect an increase in the amount of Vps4 in high density gradient fractions upon overexpression of the Bro1 domain (unpublished data), indicating that binding of ESCRT-III to Vps4 was not dramatically increased under these conditions. Together, these observations suggest that driving the interaction between Bro1 and Snf7 by overexpression of Bro1 or the Bro1 domain enhances the stability of ESCRT-III assembled at endosomal membranes despite Vps4 being present.

Bro1 binding to Snf7 inhibits Vps4-mediated disassembly of ESCRT-III in vitro
-----------------------------------------------------------------------------

The stabilizing effect exerted by Bro1 toward ESCRT-III was examined further using an in vitro system that reconstitutes Vps4-mediated disassembly of the complex. In this assay, membrane-associated ESCRT-III generated from extracts of *vps4Δ* cells were incubated with 1 mM ATP and 10 nM purified Vps4 for 10 min at 30°C, and the extent of ESCRT-III disassembly was determined by probing the amount of Snf7 that remains membrane associated after centrifugation. As shown previously ([@bib10]), this reaction condition resulted in a 50% reduction in membrane-associated Snf7 ([Fig. 3 A](#fig3){ref-type="fig"}), indicating that exogenous Vps4 has potent activity in mediating in vitro disassembly of ESCRT-III that had been preassembled in vivo. However, this activity was inhibited by ∼50% if ESCRT-III was generated from *vps4Δ* cells overexpressing the Bro1 domain and, to a lesser degree, if the source of ESCRT-III was *vps4Δ* cells overexpressing full-length Bro1 ([Fig. 3 A](#fig3){ref-type="fig"}).

![**Bro1 binding to Snf7 inhibits in vitro disassembly of ESCRT-III.** (A) 0.1 µM purified Vps4, ATP, and an ATP regeneration system were incubated with membranes isolated from *vps4Δ* yeast cells; overexpression of full-length Bro1 or the Bro1 domain (BOD) is indicated. The amount of membrane-associated Snf7 remaining after incubation at 30°C for 10 min was determined by quantitative Western blot analysis. P \< 0.001 for both samples. (B) In vitro ESCRT-III release performed in the presence or absence of ATP, 0.1 µM Vps4, and 0.1 µM GST-Bro1 domain (GST-BOD). (C) In vitro ESCRT-III release performed as in B except that the reaction was allowed to proceed for 5 min in the absence of GST-BOD or for 20 min in the absence or presence of 1 µM GST-BOD that was added either at the same time as purified Vps4 or 5 min after the addition of Vps4. (D) In vitro ESCRT-III release performed with membranes from yeast expressing wild-type Snf7 or the Snf7^Vps2MIM1^ chimera in the presence or absence of ATP, 0.1 µM Vps4, and 0.1 µM GST-BOD. Error bars show the standard deviation.](JCB_201007018_GS_Fig3){#fig3}

The inhibitory effect of Bro1 on in vitro disassembly of ESCRT-III ([Fig. 3 A](#fig3){ref-type="fig"}) was similar to the in vivo results seen in [Fig. 2](#fig2){ref-type="fig"}, wherein the stability of membrane-associated ESCRT-III was enhanced upon overexpression of Bro1 or the Bro1 domain. Although these observations support a model in which Bro1 binding to Snf7 interferes with Vps4-mediated disassembly of ESCRT-III, an alternative possibility was that excess Bro1 or Bro1 domain compromises the ESCRT-III assembly process and results in aberrant complexes refractory to Vps4. However, the addition of purified Bro1 domain (fused to GST) effectively negated in vitro Vps4-mediated disassembly of preassembled ESCRT-III generated from *vps4Δ* cells ([Fig. 3 B](#fig3){ref-type="fig"}). Moreover, this inhibitory effect was observed even if Vps4 was allowed to initiate disassembly of ESCRT-III for 5 min before the addition of GST-Bro1 domain ([Fig. 3 C](#fig3){ref-type="fig"}). Thus, Bro1 inhibition of Vps4-mediated disassembly of ESCRT-III is manifested downstream of complex assembly.

We also tested whether the inhibitory effect of the Bro1 domain relied exclusively on its ability to bind Snf7 by generating ESCRT-III from *vps4Δ* cells in which a Snf7^Vps2MIM1^ chimera was expressed in place of wild-type Snf7. In this chimera, the MIM1-like Bro1 domain--binding site is replaced with the bona fide MIM1 from Vps2 that binds the MIT domain of Vps4 ([@bib31]). The Snf7^Vps2MIM1^ chimera rescues in vitro Vps4-mediated disassembly of ESCRT-III formed in the absence of Vps2 expression, demonstrating that it effectively serves as a substrate for Vps4 ([@bib10]). Similarly, ESCRT-III assembled with Snf7^Vps2MIM1^ in place of wild-type Snf7 was susceptible to disassembly by Vps4 even upon addition of purified Bro1 domain ([Fig. 3 D](#fig3){ref-type="fig"}). We conclude that direct binding of the Bro1 domain to Snf7 inhibits Vps4-mediated disassembly of ESCRT-III.

Overexpression of Bro1 or the Bro1 domain reduces ILV budding efficiency at MVBs
--------------------------------------------------------------------------------

To evaluate whether binding of the Bro1 domain to Snf7 influences the membrane scission activity of ESCRT-III, we examined the morphology of yeast endosomes by EM and 3D tomography. Deletion of *SNF7* or genes encoding the other core ESCRT-III subunits inhibits the biogenesis of MVBs like those seen in wild-type cells ([Fig. 4 A](#fig4){ref-type="fig"} and [Video 1](http://www.jcb.org/cgi/content/full/jcb.201007018/DC1)). Instead, *snf7Δ* cells (and other ESCRT-III deletion strains; not depicted) have abnormal endosomal structures known as class E compartments, which consist of stacks of aberrantly flattened endosomes that generally lack ILVs ([Fig. 4 B](#fig4){ref-type="fig"} and [Video 2](http://www.jcb.org/cgi/content/full/jcb.201007018/DC1)), which is consistent with ESCRT-III promoting membrane scission. Expression of the *snf7^L231A/L234A^* allele in place of wild-type *SNF7* did not result in class E compartments like those seen in *snf7Δ* cells. Nevertheless, this mutation caused a sharp reduction in the number of ILVs and a gross distortion of endosomes in a manner reminiscent of the class E compartment morphology ([Fig. 4 C](#fig4){ref-type="fig"}, [Fig. 5 C](#fig5){ref-type="fig"} \[quantification\], and [Video 3](http://www.jcb.org/cgi/content/full/jcb.201007018/DC1)). This reduction in the amount of ILVs is consistent with the interpretation that Bro1 binding to Snf7 is critical for proper ESCRT-III function in vivo.

![**Endosome morphologies in cells overexpressing Bro1 or the Bro1 domain.** (A--F) 2D cross sections and 3D models from 200-nm-thick section electron tomograms. Spherical endosomal limiting membranes are depicted in yellow, whereas flattened class E compartments are depicted in various colors to discriminate discrete membranes. Lumenal vesicles are red. V, vacuole. Bars, 100 nm or 200 nm as noted. (G--L) Gallery of tomographic slices of wild-type cells with and without overexpression of Bro1 or the Bro1 domain. Freely detached ILVs are traced in red, whereas ILV budding profiles and the limiting endosomal membrane are traced in yellow. In some cases, the continuity of ILV budding profiles with the limiting endosomal membrane is out of plane in the tomographic slice but evident in the 3D reconstruction. Bars, 50 nm.](JCB_201007018_RGB_Fig4){#fig4}

![**Quantitation of endosome morphology and vesicle budding profiles.** Quantitation of the mean number of ILV budding profiles observed per MVB (A) versus the frequency distribution of the number of ILV budding profiles observed per MVB (B) observed in tomograms. Quantitation of the relative percentage of limiting versus lumenal membrane surface areas (C) and the mean ILV diameters (D) observed in tomograms. (E) The percentage of the limiting membrane incorporated into ILV budding profiles was measured for each strain. Note that no ILV budding profiles were seen for *snf7Δ* cells, but five freely detached ILVs were observed at the periphery of a class E compartment in a single tomogram of *snf7Δ* cells ([Fig. S5](http://www.jcb.org/cgi/content/full/jcb.201007018/DC1)); the rarity of this occurrence is reflected by the observation that the membrane surface area of these ILVs comprised 0.27% of the total endosomal membrane surface area in this strain. Tomograms for 12, 14, and 17 MVBs were prepared and modeled for wild-type cells, cells overexpressing the Bro1 domain, and cells overexpressing full-length Bro1, respectively. Four individual tomograms were prepared and modeled for *snf7^L231A/L234A^* cells, which contained a total of 33 MVB, VTE, and cisternal structures. Three individual tomograms were generated and modeled for *snf7Δ* cells, each containing E compartments that were composed of multiple cisternal stacks and occasionally also spherical endosomal membranes. Methods used for the preparation of the tomograms that were used to generate the measurements shown in this experiment are described in detail in the Materials and methods section.](JCB_201007018_RGB_Fig5){#fig5}

Unexpectedly, we discovered that Bro1 domain overexpression in wild-type cells increased the frequency of intralumenal invaginations that had not detached from the limiting endosomal membrane ([Fig. 4, D and E](#fig4){ref-type="fig"}; and [Videos 4](http://www.jcb.org/cgi/content/full/jcb.201007018/DC1) and [5](http://www.jcb.org/cgi/content/full/jcb.201007018/DC1)). Such ILV budding profiles are not common, with a mean of 1.2 observed per MVB in wild-type cells, but 2.4 budding profiles per MVB on average were seen upon overexpression of the Bro1 domain ([Fig. 5 A](#fig5){ref-type="fig"}). Plotting the frequency distribution of ILV budding profiles ([Fig. 5 B](#fig5){ref-type="fig"}) showed that overexpression of the Bro1 domain resulted in more instances of multiple budding profiles at individual MVBs (five budding profiles at the MVB shown in [Fig. 4 E](#fig4){ref-type="fig"}; Video 5). Overexpression of full-length Bro1 had the same effect as the Bro1 domain ([Fig. 4 F](#fig4){ref-type="fig"}; [Fig. 5, A and B](#fig5){ref-type="fig"}; and [Video 6](http://www.jcb.org/cgi/content/full/jcb.201007018/DC1)), demonstrating that the increase in ILV budding profiles was not simply caused by the absence of an activity normally provided by the C-terminal region of Bro1. A gallery of tomograms highlighting ILV budding profiles versus detached ILVs at individual MVBs in wild-type cells with and without overexpression of Bro1 or the Bro1 domain is shown in [Fig. 4 (G--L)](#fig4){ref-type="fig"}.

The low frequency of ILV budding profiles in wild-type yeast presumably reflects the rapid rate at which membrane scission normally occurs. This process is most likely delayed rather than accelerated in response to Bro1 or Bro1 domain overexpression because quantitation of membrane surface areas showed a decrease in the lumenal membrane content and a corresponding increase in the amount of limiting membrane ([Fig. 5 C](#fig5){ref-type="fig"}), although the mean vesicle diameter did not change ([Fig. 5 D](#fig5){ref-type="fig"}). In contrast, an acceleration of ILV formation would be expected to show an increase in the amount of lumenal membrane content within endosomes, as is observed in yeast lacking Ist1 ([@bib30]), an accessory ESCRT-III protein that inhibits Vps4 activity ([@bib11]). Compared with wild-type cells, the ratio of lumenal to limiting membrane surface area was lower upon mutation of the Bro1 domain--binding site in Snf7 (*snf7^L231A/L234A^*; 23.3% of total endosomal membrane surface area was lumenal; [Fig. 5 C](#fig5){ref-type="fig"}), whereas *snf7Δ* cells were almost exclusively devoid of lumenal membranes (0.27% of the total endosomal membrane surface area; [Fig. 5 C](#fig5){ref-type="fig"}), which is consistent with the stronger effects on endosomal morphology caused by these mutations ([Fig. 4](#fig4){ref-type="fig"}).

Measurements of tomograms further revealed that the amount of membrane incorporated into ILV budding profiles in wild-type cells accounted for only 6.3% of the limiting endosomal membrane surface area. In contrast, overexpression of Bro1 or the Bro1 domain resulted in the incorporation of 18.6% and 17.5%, respectively ([Fig. 5 E](#fig5){ref-type="fig"}), which is proportional to the increased frequency of ILV budding profiles observed under these conditions ([Fig. 5 A](#fig5){ref-type="fig"}). Despite the increase in the number of ILV budding profiles, their overall morphology was not altered significantly, as neither the diameter of the vesicles attached to the limiting endosomal membrane ([Fig. S4 A](http://www.jcb.org/cgi/content/full/jcb.201007018/DC1)) nor the diameter of the membrane neck at ILV budding profiles (Fig. S4 B) were statistically different in wild-type cells with or without overexpression of Bro1 or the Bro1 domain.

Cargo sorting and deubiquitination are not affected by Bro1 or Bro1 domain overexpression in wild-type cells
------------------------------------------------------------------------------------------------------------

Transmembrane proteins sorted into the ILVs of MVBs are ultimately delivered to the vacuole lumen upon MVB--vacuole fusion, but disrupting the activity of any of the ESCRTs results in mislocalization of these cargoes to the vacuole membrane and their accumulation at class E compartments ([@bib32]). Therefore, we evaluated how the effects on ILV budding revealed by EM tomography ([Fig. 4](#fig4){ref-type="fig"}) impacted the efficiency of cargo sorting using live cell fluorescence microscopy of yeast expressing GFP fused to the cytoplasmic domain of carboxypeptidase S (GFP-CPS). We previously reported mislocalization of GFP-CPS upon mutation of the Snf7-binding site in the Bro1 domain ([@bib20]). Similarly, mislocalization of GFP-CPS occurred both in *snf7Δ* cells and in s*nf7^L231A/L234A^* cells lacking the Bro1-binding site within Snf7 ([Fig. 6 A](#fig6){ref-type="fig"}), which was consistent with the strong reduction in ILV formation caused by these mutations ([Fig. 5](#fig5){ref-type="fig"}). Delivery of GFP-CPS into the vacuole lumen in wild-type cells was only mildly affected upon overexpression of the Bro1 domain ([Fig. 6 A](#fig6){ref-type="fig"}), whereas full-length Bro1 overexpression did not appear to cause significant cargo mislocalization ([@bib24]).

![**Cargo sorting and deubiquitination.** (A) Fluorescence and DIC microscopy of cells expressing GFP-CPS. Bars, 2 µm. (B) Western blot analysis of anti-CPS immunoprecipitates. IB, immunoblotting.](JCB_201007018_GS_Fig6){#fig6}

Doa4 is the Ub hydrolase that deubiquitinates CPS and other MVB vesicle cargoes ([@bib12]; [@bib17]; [@bib23]), and its activity is stimulated upon binding to Bro1 ([@bib36]). This process occurs efficiently in wild-type cells, resulting in detection of very little ubiquitinated CPS (Ub-CPS; [Fig. 6 B](#fig6){ref-type="fig"}). In contrast, Ub-CPS accumulated upon deletion of *SNF7* or upon mutation of its Bro1 domain--binding site (*snf7^L231A/L234A^*; [Fig. 6 B](#fig6){ref-type="fig"}), demonstrating that its interaction with Snf7 is important for Bro1 to promote Doa4 activity at endosomes. Conversely, overexpression of Bro1 or the Bro1 domain had no observable effects on CPS deubiquitination ([Fig. 6 B](#fig6){ref-type="fig"}), indicating that the enhancement of ESCRT-III stability and reduced efficiency in membrane scission is not a consequence of altered Doa4 function.

Discussion
==========

In vitro studies have pointed to the assembly of ESCRT-III being crucial to the membrane scission event that results in detachment of ILVs ([@bib53]; [@bib52]). Although the specific mechanism by which ESCRT-III executes this activity is unclear, its role in severing membrane connections is supported by in vivo studies of mammalian cells, showing a requirement for ESCRT-III in cytokinesis and retroviral budding, both of which are membrane scission events that are topologically equivalent to ILV formation at MVBs ([@bib27]). Genetic dissection of the mechanism of action for ESCRT-III at endosomes in *S. cerevisiae* has been elusive because of the formation of aberrant class E compartments rather than MVBs in mutant yeast that generally lack functional ESCRT complexes ([@bib37]; [@bib32]; [@bib24]; [@bib29]). In this study, we describe a potential role for Bro1 in regulating ESCRT-III by demonstrating that overexpression of either full-length Bro1 or its N-terminal Bro1 domain stabilizes ESCRT-III polymers and reduces the efficiency of ILV detachment from the limiting endosomal membrane in yeast that contain an otherwise wild-type ESCRT machinery.

ILV budding profiles in yeast are infrequently observed, even in thick sections imaged by 3D EM tomography, presumably because of the rapid rate at which membrane deformation and scission occur. The increased frequency of budding profiles caused by overexpression of Bro1 or the Bro1 domain must be interpreted as a reduction in ILV budding efficiency rather than an acceleration because these conditions also resulted in significantly less lumenal membrane content within MVBs. In the absence of monitoring this process in real time, it is impossible to exclude whether at least some of the ILV budding profiles are dead-end structures that fail to complete membrane scission. However, the ILVs seen in cells overexpressing Bro1 or the Bro1 domain appeared structurally normal. Neither their overall mean diameter nor the dimensions at the necks of the budding profiles were significantly different from the same measurements in wild-type cells, suggesting that these ILVs will eventually detach from the limiting endosomal membrane.

The specific mechanism underlying the reduced efficiency of ILV budding resulting from overexpression of Bro1 or the Bro1 domain is unclear, but a clue comes from our finding that this condition correlates with increased detection of Snf7 and Vps24, both core ESCRT-III subunits, in a high molecular mass polymer despite wild-type Vps4 expression. Vps4 is the AAA-ATPase that catalyzes disassembly of ESCRT-III ([@bib5]), which accounts for very little of the assembled complex existing at steady-state ([@bib47]). Based on in vitro reconstitution of ILV budding, Vps4 is thought to function indirectly in membrane scission by recycling ESCRT-III subunits for repeated rounds of assembly ([@bib53]; [@bib52]). Given the intermediate degree to which Snf7 polymers are stabilized upon Bro1 or Bro1 domain overexpression (only ∼30% of the total amount of Snf7 that is trapped as a polymer in *vps4Δ* cells), it seems unlikely that a deficiency of free ESCRT-III subunits exists for complex assembly and subsequent execution of membrane scission. However, we presently cannot determine whether Bro1-mediated stabilization of ESCRT-III is the direct cause of the reduced efficiency in ILV budding, which would suggest an active role for Vps4 during membrane scission in vivo. Nevertheless, the possibility that membrane scission might be coupled to Vps4 activity is consistent with our previous discovery by EM tomography that MVBs have significantly more ILVs in the absence of Ist1 ([@bib30]), an accessory ESCRT-III protein that negatively regulates Vps4 by inhibiting its binding to ESCRT-III ([@bib11]). An active role for Vps4 in membrane scission might also explain why overexpression of catalytically inactive Vps4 in mammalian cells results in an increased frequency of ILV budding profiles at endosomes ([@bib41]).

The membrane scission activity of ESCRT-III in vitro is potently stimulated by ESCRT-II ([@bib16]), which is thought to trigger ESCRT-III polymerization through its direct binding to Vps20 ([@bib42]). Unlike ESCRT-III, however, ESCRT-II is not required for the budding of human immunodeficiency virus-1 (HIV-1; [@bib21]), raising the question of how ESCRT-III assembly is stimulated at the site of viral budding. The p6 domain of the Gag polyprotein of HIV-1 binds both to Alix ([@bib44]) and to TSG101, a subunit of ESCRT-I ([@bib14]; [@bib25]; [@bib51]). The yeast orthologue of TSG101 (Vps23) also binds Vps20 ([@bib7]; [@bib48]), but an interaction between TSG101 and ESCRT-III has not been reported. Binding of Alix alone to p6 is sufficient to promote HIV-1 budding ([@bib13]; [@bib50]), but whether this interaction facilitates ESCRT-III assembly is unknown. Our results suggest that Bro1 in yeast lacks this activity because its ability to stabilize ESCRT-III when overexpressed was dependent on the presence of Vps20.

Bro1 exerts its stabilization effect toward ESCRT-III downstream of complex assembly because the addition of exogenous Bro1 domain to preassembled ESCRT-III was sufficient to protect the complex from Vps4-mediated disassembly in vitro. Direct binding to Snf7 was required for Bro1 to inhibit ESCRT-III disassembly both in vivo and in vitro. The site at the C terminus of Snf7 to which the Bro1 domain binds is conserved, as a similar motif was identified at the C terminus of human CHMP4 proteins and shown to be required for binding to the Bro1 domain of Alix ([@bib26]). The amino acid sequence of this motif and its position near the C terminus of Snf7 resemble the MIM1 sites in Vps2/CHMP2 and Did2/CHMP1 that bind directly to the MIT domain of Vps4, but this site in Snf7 and CHMP4 proteins lacks residues critical for the MIT interaction ([@bib31]; [@bib45]). Thus, it is unlikely that Bro1 stabilizes ESCRT-III by directly masking a site at which Vps4 might bind Snf7. Located upstream of the MIM1-like site in Snf7 and CHMP4 proteins is a second motif (MIM2) that binds weakly to the Vps4 MIT domain in vitro ([@bib19]). Although it is possible that the Bro1 domain interaction sterically shields Vps4 recognition of the MIM2 site in Snf7, testing this hypothesis has been problematic because the Snf7--Vps4 interaction is so weak that we cannot detect binding of either full-length Snf7 or a fragment encompassing MIM2 either to full-length Vps4 or to the Vps4 MIT domain in isolation (unpublished data).

Snf7 is the predominant subunit of the ESCRT-III polymer ([@bib47]) and is critical for the membrane scission activity of the complex in vitro ([@bib53]). EM tomography suggests the membrane scission activity of ESCRT-III at endosomes in yeast relies on Snf7 binding to the Bro1 domain because *snf7^L231A/L234A^* cells, which have otherwise wild-type ESCRT protein activity, exhibit a strong reduction in the number of ILVs and a concomitant expansion of the limiting endosomal membrane, a morphology reminiscent of class E compartments seen in *snf7Δ* cells and other ESCRT mutant strains. The residual localization of full-length Bro1 to endosomes in *snf7^L231A/L234A^* cells might account for the few ILVs observed because complete removal of Bro1 function by deletion of the *BRO1* gene results in class E compartments rather than MVBs ([@bib24]; [@bib36]). Bro1 stimulates transmembrane protein cargo deubiquitination at endosomes by promoting both recruitment and activation of the Doa4 Ub hydrolase ([@bib24]; [@bib36]). However, this activity alone cannot account for the importance of the Bro1--Snf7 interaction during membrane scission because mutations that specifically disable Bro1 from stimulating Doa4 do not impair ILV formation, nor does replacement of wild-type *DOA4* with nonfunctional alleles ([@bib36]).

The strong reduction in ILV formation seen in *snf7^L231A/L234A^* cells is consistent with the failure in delivery of CPS to the vacuole lumen via the MVB pathway. Given the central role Bro1 has in regulating deubiquitination at endosomes, it is not surprising that disruption of the Bro1 domain--binding site in Snf7 caused a strong accumulation of Ub-CPS. However, the efficiency of cargo deubiquitination controlled by endogenous full-length Bro1 in wild-type cells suffered virtually no reduction upon overexpression of the Bro1 domain. The C terminus of Bro1 stimulates Doa4 Ub hydrolase activity ([@bib36]), and this region is absent from the Bro1 domain ([Fig. 1 A](#fig1){ref-type="fig"}), which would compete with endogenous Bro1 for binding to Snf7. Although its interaction with Snf7 comprises the primary mechanism for endosomal recruitment of Bro1, a small amount of Bro1 is detectable at endosomes if this interaction has been disabled ([Fig. 1 C](#fig1){ref-type="fig"}; [@bib20]). The fact that cargo deubiquitination is not significantly compromised by Bro1 domain overexpression suggests that the Snf7-independent mechanism of Bro1 recruitment to endosomes (which has yet to be defined) might be sufficient to maintain Doa4 function.

The inhibition of ESCRT-III disassembly resulting from Bro1 binding to Snf7 might be critical for ESCRT-III reaching a state of assembly necessary to execute membrane scission, explaining the strong reduction in the efficiency of ILV formation observed upon disruption of the Bro1-binding site in Snf7. A similar stabilizing role for Alix would be consistent with observations that disruption of its interaction with CHMP4 proteins impairs cytokinesis and reduces the efficiency of retrovirus budding ([@bib8]; [@bib13]; [@bib28]; [@bib50]; [@bib9]). At endosomes, a regulatory function in promoting ESCRT-III assembly would place Bro1 at the appropriate time and place to coordinate deubiquitination of transmembrane protein cargoes with the detachment of ILVs. However, a mechanism for coupling these seemingly separate activities of Bro1 has yet to be discovered.

Materials and methods
=====================

Yeast strains and plasmid constructions
---------------------------------------

Standard protocols were used to construct all yeast strains and plasmids described in [Tables I](#tbl1){ref-type="table"} and [II](#tbl2){ref-type="table"} ([@bib22]). The bacterial expression plasmid encoding *SNF7-HA* (pGO619) was constructed in vector pST39 ([@bib46]) using a PCR product created from the wild-type *SNF7* coding sequence and a reverse primer that includes one copy of the HA epitope. The L231A/L234A point mutations were created by site-directed mutagenesis of pGO619, yielding pGO621. The 2-µm plasmid encoding the Bro1 domain (pMWM3) was constructed by homologous recombination of linearized pRS426 with a PCR product containing the Bro1 promoter and Bro1 codons 1--387.

###### 

*S. cerevisiae* strains used in this study

  Name      Genotype                                                       Reference
  --------- -------------------------------------------------------------- ------------
  SEY6210   Mata leu2-3,112 ura3-52 his3Δ200 trp1-Δ901 lys2-Δ801 suc2-Δ9   [@bib38]
  MBY3      SEY6210; vps4Δ::TRP1                                           [@bib4]
  TVY1      SEY6210; pep4Δ::LEU2                                           [@bib15]
  MWY22     SEY6210; pep4Δ::LEU2 snf7Δ::HIS3                               This study
  MWY24     SEY6210; snf7Δ::HIS3                                           This study
  MWY25     SEY6210; snf7L231A/L234A::KAN                                  This study
  MWY26     SEY6210; snf7L231A/L234A-KAN vps4::TRP1                        This study
  CRY181    SEY6210; snf7L231A/L234A-KAN vps4::TRP1 pep4Δ::LEU2            This study
  EEY12     SEY6210; snf7Δ::HIS3 vps4Δ::TRP1                               [@bib6]
  MBY41     SEY6210; vps20Δ::HIS3 vps4Δ::TRP1                              [@bib6]
  GOY66     SEY6210; bro1Δ::HIS3 vps4Δ::TRP1                               [@bib33]
  GOY65     SEY6210; bro1Δ::HIS3                                           [@bib33]
  EEY2-1    SEY6210; vps20Δ::HIS3                                          [@bib6]
  MBY52     SEY6210; vps4Δ::TRP1 pep4Δ::LEU2 prb1Δ::LEU2                   [@bib18]
  JPY140    SEY6210; vps4Δ::TRP1 pep4Δ::LEU2 snf7Δ::HIS3                   [@bib10]
  CRY39     SEY6210; Vps23-GFP::KAN                                        [@bib30]
  CRY40     SEY6210; Vps23-GFP::KAN vps4Δ::TRP1                            [@bib30]
  GOY150    SEY6210; Vps36-GFP::HIS3                                       [@bib30]
  GOY151    SEY6210; Vps36-GFP::HIS3 vps4Δ::TRP1                           [@bib30]
  GOY74     SEY6210; Doa4-GFP::HIS3                                        [@bib24]
  GOY75     SEY6210; Doa4-GFP::HIS3 vps4Δ::TRP1                            [@bib24]

###### 

Plasmids used in this study

  Plasmid               Protein expressed      Description
  --------------------- ---------------------- ------------------------------------------
  pGO337                GFP-Bro1 1-387         GFP-Bro1^1-387^ URA3 Ap^R^ (pRS416)
  pGO339                GFP-Bro16              GFP-Bro1 URA3 Ap^R^ (pRS41)
  pGO47                 GFP-CPS                [@bib32]
  pCR180                GFP-Sna3               URA3 Ap^R^ (pRS415) GFP-Sna3
  pGO547                Snf7                   pST39 Shine-Delgarno Snf7
  pGO619                Snf7-HA                pST39 Shine-Delgarno Snf7-HA
  pGO621                Snf7^L231A/L234A^-HA   pST39 Shine-Delgarno Snf7 L231A/L234A-HA
  pGEX-4T1              GST                    GE Healthcare
  pGO626                GST-Bro1^1-387^-HA     pGEX-4T1 GST-Bro1 1-387-HA
  pMB54                 GST-Vps4               [@bib2]
  pGO216                Bro1                   URA3 ApR (pRS426) Bro1
  pMWM3                 Bro11-387              URA3 ApR (pRS426) Bro11-387
  pRS426 Snf7           Snf7                   [@bib10]
  pRS426 Snf7Vps2MIM1   Snf7Vps2MIM1           [@bib10]

Protein interaction experiments
-------------------------------

Lysates of bacteria expressing Snf7-HA or Snf7^L231A/L234A^-HA were prepared from cultures of BL21 (DE3; Agilent Technologies) transformed with pGO619 or pGO621; protein expression was induced at 20°C for 20 h after the addition of 0.5 mM isopropyl-β-[d]{.smallcaps}-thiogalactoside. Purified GST-Bro1 domain was obtained on glutathione Sepharose resin (GE Healthcare) from lysates of BL21 (DE3) that had been transformed with a plasmid encoding this gene fusion ([@bib20]) and induced to express recombinant protein. For in vitro pull-down experiments, glutathione Sepharose and 5 µg GST-Bro1 domain (or GST alone) were incubated for 1 h at 4°C with lysates prepared from bacteria expressing Snf7-HA or Snf7^L231/L234A^-HA. Bound proteins were recovered by centrifugation of the resin, which was washed thrice with ice-cold PBS + 0.5% Triton X-100, then washed twice with ice-cold PBS. Bound proteins were eluted from the resin by boiling in Laemmli sample buffer, resolved by SDS-PAGE, and transferred to nitrocellulose for Western blot analysis using anti-HA monoclonal antiserum (Roche). 10% of the amount of GST or GST-Bro1 used in each pull-down was resolved by SDS-PAGE and analyzed by Coomassie staining.

Microscopy
----------

Fluorescence microscopy of cells labeled with *N*-\[3-triethylammoniumpro-pyl\]-4-\[*p*-diethylaminophenylhexatrienyl\] pyridinium dibromide (FM4-64) and/or expressing GFP was performed as described previously ([@bib24]) using a microscope (Axioplan 2; Carl Zeiss, Inc.) equipped with an NA 1.40 oil immersion 100× objective (Carl Zeiss, Inc.) at room temperature in minimal media. Differential interference contrast (DIC) and fluorescence microscopy images were acquired with a digital camera (Cooke Sensicam; Applied Scientific Instruments, Inc.) and processed using Slidebook (Intelligent Imaging Innovations) and Photoshop software (version CS2; Adobe).

For EM, yeast cells were high pressure frozen and freeze substituted as previously described ([@bib29]; [@bib36]) and embedded at −60°C in Lowicryl HM20 (Polysciences). Plastic blocks were trimmed and cut in 80-nm-thin sections and 250-nm-thick sections with a microtome (Leica) and placed on rhodium-plated copper slot grids. Tomographic samples were stained en bloc with 0.1% uranyl acetate and 0.25% glutaraldehyde as a minimal fixative with no additional after staining except for *snf7Δ*, which required 0.1% uranyl acetate and 2% glutaraldehyde for sufficient preservation for tomography. Thick sections were mapped on a transmission EM (Phillips CM10) at 80 kv, then a Tecnai 30 (FEI) at 300 kv was used for dual-tilt series images collected from 60 to −60° with 1° increments. Tilt series were shot at 31,000× magnification with a 0.764-nm working pixel (binning 2) and repeated at a 90° rotation for dual-axis tomography. 15-nm fiducial gold was used to coat sections on both sides for reconstruction of back projections using IMOD software. Manually assigned contours of the endosomal limiting membrane at the inner leaflet were used to measure the surface of the bilayers periodically every 3.85 nm and calculated using imodmesh. Best-fit sphere models were used to measure the diameters of nearly spherical lumenal vesicles from the outer leaflet of the membrane bilayers. Videos 1--6 were made from IMOD images and completed in QuickTime. Quantitation of ILV budding profiles/MVB were normalized to the mean percent MVB accounted for in the tomograms to more accurately represent the number of ILV budding profiles per MVB.

Isopycnic density gradient centrifugation
-----------------------------------------

For the resolution of native ESCRT complexes, 20 A~600~ equivalents of cells were converted to spheroplasts, resuspended in 1 ml ice-cold lysis buffer (200 mM sorbitol, 50 mM potassium acetate, 20 mM Hepes, pH 7.2, and 2 mM EDTA) supplemented with protease inhibitors, and homogenized on ice. Soluble and membrane fractions were separated by spinning the lysates at 13,000 *g* for 15 min at 4°C. The resulting membrane pellet was resuspended in 950 µl lysis buffer, then solubilized by the addition of 0.5% Triton X-100 and rotation at 4°C for 30 min. Solubilized membranes were loaded onto the top of a 10--70% sucrose gradient prepared with the Tris gradient system (Biocomp Instruments) using 10% and 70% sucrose stocks prepared in 200 mM sorbitol, 50 mM potassium acetate, 20 mM Hepes, pH 7.2, and 2 mM EDTA. The gradient was subjected to centrifugation in an SW41 rotor (Beckman Coulter) at 100,000 *g* for 16--20 h at 4°C, and fractions were collected from the top. Sodium deoxycholate (0.015% final) and trichloroacetic acid (10% final) were added to each fraction, and proteins were precipitated on ice for at least 30 min, followed by centrifugation at 13,000 *g* for 10 min. Insoluble material was reprecipitated twice by sonication into ice-cold acetone and centrifugation, then sonicated into Laemmli sample buffer and resolved by SDS-PAGE, transferred to nitrocellulose, and examined by Western blotting using antisera against Snf7, Vps24, or GFP (Roche). Quantitation was performed on triplicate experiments by incubating membranes with Alexa Fluor 680 secondary antibody (Invitrogen) and visualizing with an infrared imager (Odyssey; LI-COR Biosciences). Bands were quantitated with Odyssey software (version 2.1). For the *snf7^L231A/L234A^* strain, 40 A~600~ equivalents were used because of decreased detection of the mutant version of the protein. The presence of 1% Triton X-100 throughout the sucrose gradient yielded identical results to gradients performed where Triton X-100 was omitted from the gradient.

In vitro ESCRT-III release assay
--------------------------------

The in vitro ESCRT-III release assay was performed as previously described ([@bib10]). Purified Vps4 and an ATP regeneration system (10 mM phosphocreatine, 10 U/ml creatine phosphokinase, and 1 mM ATP) were added to yeast membrane fractions containing ESCRT-III complexes ([@bib4]; [@bib2]). Membranes were generated from sheroplasted cells that were lysed under native conditions and homogenized, then resuspended in ATPase reaction buffer (100 mM KOAc, 20 mM Hepes, pH 7.4, and 5 mM MgOAc) and passed through an 18-G needle three times followed by a 30-G needle five times to homogenize the membranes. Reactions were allowed to incubate for 10 min at 30°C, then subjected to centrifugation at 13,000 *g* to separate the membrane-associated and soluble ESCRT-III. SDS-PAGE followed by Western blot analyses was performed with anti-Snf7 antiserum and quantitated using ImageQuant software.

Ub-CPS immunoprecipitation
--------------------------

Detection of Ub-CPS was performed as described previously ([@bib17]). The vacuolar protease gene *PEP4* was deleted in all strains to reduce the nonspecific cleavage of Ub from CPS after cellular lysis. 10 A~600~ equivalents of cells were harvested and precipitated by the addition of trichloroacetic acid (10% final concentration). Whole cell lysates were generated by glass bead disruption in urea buffer (6 M urea, 1% SDS, 50 mM, Tris pH 7.5, 1 mM EDTA, and 5 mM NEM), spun at 13,000 *g* to clear, the supernatant was transferred to a new tube, and CPS was immunoprecipitated with anti-CPS polyclonal antiserum and protein A--Sepharose. Immunoprecipitates were spun down and washed four times, and the beads dried. Samples were resuspended in sample buffer, and 0.5 OD~600~ equivalents were subjected to SDS-PAGE, transferred to nitrocellulose, which was autoclaved twice, blocked in 20% fetal calf serum, and probed with antibodies against Ub (Invitrogen) or CPS.

Online supplemental material
----------------------------

Fig. S1 shows that Bro1 binding to Snf7 is required for the stabilization of ESCRT-III polymers at endosomes. Fig. S2 shows that overexpression of the Bro1 domain stabilizes ESCRT-III subunit Vps24 at the endosomal membrane. Fig. S3 reveals that the subcellular distribution of ESCRT-III proteins is not altered by overexpression of full-length Bro1 or the Bro1 domain. Fig. S4 demonstrates that the diameters of the membrane necks and vesicles contained within ILV budding profiles do not significantly between wild-type cells and cells overexpressing Bro1 or the Bro1 domain. Fig. S5 shows a tomographic model of an *snf7Δ* class E compartment that contains five intralumenal vesicles. Video 1 shows a 3D reconstruction of MVBs from a wild-type cell, the top MVB contains a vesicle budding profile. Video 2 contains a 3D reconstruction of an *snf7Δ* class E compartment. Video 3 shows endosomal structures from *snf7^L231A/L234A^* cells in which the endosomes appear to be intermediates between wild-type MVBs and E compartments. Video 4 highlights an MVB from cells overexpressing the Bro1 domain. The MVB contains a single ILV budding profile and several intralumenal vesicles. Video 5 contains a tomographic model of an MVB from cells overexpressing the Bro1 domain in which five simultaneous ILV budding profiles can be observed. Video 6 shows a cluster of three endosomes from cells overexpressing full-length Bro1. Two ILV budding profiles can be seen within the tubular endosome. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.201007018/DC1>.
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